osimertinib glioblastoma has emerged as a groundbreaking development in the field of oncology. This combination therapy, which involves the use of osimertinib, a third-generation EGFR inhibitor, and glioblastoma, a highly aggressive brain tumor, holds significant promise for improving patient outcomes. In this article, we will delve into the intricacies of osimertinib glioblastoma, explore its...